| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2012PNAS..10913237Z |
| P356 | DOI | 10.1073/PNAS.1200105109 |
| P932 | PMC publication ID | 3421218 |
| P698 | PubMed publication ID | 22733765 |
| P5875 | ResearchGate publication ID | 228066992 |
| P2093 | author name string | Qian Zhang | |
| Kian Kani | |||
| Ralf Landgraf | |||
| Euisun Park | |||
| P2860 | cites work | An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor | Q24293598 |
| Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha | Q24307630 | ||
| Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains | Q24307661 | ||
| Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 | Q24321567 | ||
| ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation | Q24621754 | ||
| SWISS-MODEL: An automated protein homology-modeling server | Q24672647 | ||
| Structure of the extracellular region of HER3 reveals an interdomain tether | Q27639450 | ||
| Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3 | Q27646596 | ||
| Activation-dependent clustering of the erbB2 receptor tyrosine kinase detected by scanning near-field optical microscopy | Q28143449 | ||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 | ||
| Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. | Q35234347 | ||
| Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers | Q35566231 | ||
| Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity | Q35684026 | ||
| The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors | Q36334739 | ||
| Oligomerization of epidermal growth factor receptors on A431 cells studied by time-resolved fluorescence imaging microscopy. A stereochemical model for tyrosine kinase receptor activation | Q36535729 | ||
| Higher-order association states of cellular ERBB3 probed with photo-cross-linkable aptamers | Q37355330 | ||
| Equilibrium mechanisms of receptor clustering | Q37595839 | ||
| Heregulin reverses the oligomerization of HER3. | Q38310163 | ||
| Predominance of activated EGFR higher-order oligomers on the cell surface. | Q39927376 | ||
| Quantitative characterization of the large-scale association of ErbB1 and ErbB2 by flow cytometric homo-FRET measurements. | Q39980973 | ||
| Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis | Q40402524 | ||
| Proxy activation of protein ErbB2 by heterologous ligands implies a heterotetrameric mode of receptor tyrosine kinase interaction | Q42141978 | ||
| Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth | Q44120544 | ||
| Mapping ErbB receptors on breast cancer cell membranes during signal transduction | Q50336733 | ||
| Preparation and characterization of Alexa Fluor 594-labeled epidermal growth factor for fluorescence resonance energy transfer studies: application to the epidermal growth factor receptor | Q75201152 | ||
| P433 | issue | 33 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phosphorylation | Q242736 |
| Erb-b2 receptor tyrosine kinase 2 | Q415271 | ||
| identical protein binding | Q14762994 | ||
| P304 | page(s) | 13237-13242 | |
| P577 | publication date | 2012-06-25 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling | |
| P478 | volume | 109 |
| Q35674768 | A structural perspective on the regulation of the epidermal growth factor receptor |
| Q35917462 | Analysis of the Role of the C-Terminal Tail in the Regulation of the Epidermal Growth Factor Receptor |
| Q36670915 | Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation. |
| Q38876644 | Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib |
| Q38694995 | CRISPR-assisted receptor deletion reveals distinct roles for ERBB2 and ERBB3 in skin keratinocytes |
| Q27323236 | Coarse-grained molecular simulation of epidermal growth factor receptor protein tyrosine kinase multi-site self-phosphorylation |
| Q35841734 | Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer |
| Q35643021 | Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization |
| Q47396247 | Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. |
| Q37234153 | Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging |
| Q42081733 | EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms. |
| Q30827493 | EGFR oligomerization organizes kinase-active dimers into competent signalling platforms |
| Q38263000 | ErbB receptors as prognostic and therapeutic drug targets in bone and soft tissue sarcomas |
| Q36974435 | Exploring higher-order EGFR oligomerisation and phosphorylation--a combined experimental and theoretical approach |
| Q37588232 | HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status |
| Q27315979 | Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk |
| Q35121287 | Kinase activator-receiver preference in ErbB heterodimers is determined by intracellular regions and is not coupled to extracellular asymmetry |
| Q37690877 | Localisation Microscopy of Breast Epithelial ErbB-2 Receptors and Gap Junctions: Trafficking after γ-Irradiation, Neuregulin-1β, and Trastuzumab Application. |
| Q33883884 | Mechanisms of activation of receptor tyrosine kinases: monomers or dimers |
| Q38734026 | Melatonin Represses Metastasis in Her2-Postive Human Breast Cancer Cells by Suppressing RSK2 Expression |
| Q53078543 | Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. |
| Q36993693 | Molecular basis for multimerization in the activation of the epidermal growth factor receptor |
| Q27306737 | Orchestration of ErbB3 signaling through heterointeractions and homointeractions |
| Q36170761 | Pari passu dimers of dimers |
| Q39089524 | Piecing it together: Unraveling the elusive structure-function relationship in single-pass membrane receptors |
| Q34735615 | Profiling epidermal growth factor receptor and heregulin receptor 3 heteromerization using receptor tyrosine kinase heteromer investigation technology |
| Q91620677 | Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples |
| Q35461504 | RETRACTED: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody |
| Q33566959 | Recruitment of the adaptor protein Grb2 to EGFR tetramers |
| Q91721637 | Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers |
| Q54314774 | Somatic mutations of the HER2 in metastatic breast cancer. |
| Q35577623 | Structure-based development and optimization of therapy antibody drugs against TNFα. |
| Q39085589 | Suppression of heregulin β signaling by the single N-glycan deletion mutant of soluble ErbB3 protein. |
| Q38364887 | Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies. |
| Q38129286 | Targeting the ERBB family in cancer: couples therapy |
| Q36545226 | The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer |
| Q37643945 | erbB3 is an active tyrosine kinase capable of homo- and heterointeractions |
Search more.